|Bid||76.16 x 800|
|Ask||78.00 x 800|
|Day's Range||73.50 - 76.44|
|52 Week Range||71.84 - 96.79|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||36.79|
|Earnings Date||Apr 27, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||91.67|
In honor of Rare Disease Day on February 29th, Incyte (NASDAQ:INCY) is proud to announce the launch of Rare Reflections: MPNs Unmasked, a disease awareness initiative focused on raising awareness of and educating about myeloproliferative neoplasms (MPNs), a group of rare, chronic blood cancers.
Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community. Each year, the Incyte Ingenuity Award is expected to fund, up to $100,000, one innovative program, idea or initiative that fosters collaboration within the GVHD community to address a specific unmet need.
Incyte Announces Positive Topline Results from Phase 3 TRuE-AD Program evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
Incyte stock climbed higher Thursday after the biotech company reported $579.39 million in sales, beating fourth-quarter estimates. Incyte earnings of 62 cents a share also topped.
The drug company (INCY)reported earnings early Thursday that beat analyst expectations, but the stock was climbing in premarket trading. Incyte (ticker: INCY) reported non-GAAP diluted earnings of 65 cents per share for the fourth quarter of 2019, beating the S&P Capital IQ Consensus of 56 cents, and the FactSet consensus of 60 cents. Shares of Incyte were up 1.8% to $77.18 in premarket trading.
Incyte (INCY) delivered earnings and revenue surprises of 12.07% and 1.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
Incyte (Nasdaq:INCY) announced today that it will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. ET in Boston.
Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.